Management of Latent TB in Pre-Lung Transplant Candidates
All lung transplant candidates with positive latent TB screening should be evaluated by an infectious disease specialist and receive TB preventive therapy, ideally completed before transplantation. 1
Screening Protocol
Perform TB screening in all lung transplant candidates with no previous TB history using:
- TB IGRA test (QuantiFERON) or tuberculin skin test 1
- Chest radiograph to rule out active disease 1
- Detailed TB risk factor assessment including endemic exposures, prior TB contacts, and immunosuppressive history 2, 3
- Consider chest CT scan if chest X-ray is inconclusive, as residual lesions on CT are an independent risk factor for post-transplant TB (OR 11.5) even with negative TST 4
Treatment Approach
When to Treat
- Treat all candidates with positive LTBI screening unless they have documented prior adequate LTBI or TB treatment 5
- In the Mayo Clinic cohort, 76% of positive QFT patients were recommended treatment; most who didn't receive treatment had prior documented therapy 5
Preferred Regimen for Lung Transplant Candidates
Isoniazid monotherapy remains the preferred regimen in the transplant population despite newer short-course options available for immunocompetent hosts 6, 7. Here's why:
- 6-9 months of isoniazid is recommended as the standard regimen 6, 3
- While 3-4 month rifamycin-based regimens (rifampin/rifapentine) are preferred in general populations 6, they are problematic in transplant due to significant drug-drug interactions with calcineurin inhibitors (tacrolimus/cyclosporine) 8, 7
- If rifampin is used post-transplant, calcineurin inhibitor doses must be increased by an average of 215% with close monitoring for 2-3 weeks 8
Timing Considerations
Ideally complete LTBI treatment before transplantation 1, 2:
- In practice, 45% of patients initiate treatment pre-transplant and 55% post-transplant 5
- Lung recipients are at highest risk and should receive preventive therapy even if the donor had latent TB 1
- Treatment can be completed post-transplant if time constraints prevent pre-transplant completion
Treatment Completion and Monitoring
- 73-75% of patients who initiate LTBI treatment complete it successfully 5
- Adverse events are rare (7%) with isoniazid 5
- Monitor liver function tests during treatment, especially in the post-transplant period
Critical Pitfalls to Avoid
Don't skip chest CT if chest X-ray is normal but risk factors are present - residual lesions on CT predict TB reactivation even with negative screening tests 4
Avoid azathioprine and mTOR inhibitors (everolimus) if possible in high-risk patients - both are independent risk factors for post-transplant TB (OR 10.6 and 6.7 respectively) 4
Don't assume negative screening tests rule out future TB - 7 patients in one cohort developed active TB despite various treatment scenarios, including 3 who completed LTBI treatment 5
Most post-transplant TB occurs within the first year (88.89% of cases), so maintain high clinical suspicion during this period 8
Post-Transplant Surveillance
Even with completed LTBI treatment, maintain vigilance for TB reactivation, particularly:
- During the first 12 months post-transplant 8
- In patients with residual CT lesions 4
- When using azathioprine or mTOR inhibitors 4
- Pulmonary presentation is most common (86.67%) but extrapulmonary disease occurs 8
The evidence demonstrates that systematic screening, infectious disease consultation (93% evaluation rate), and treatment completion (73% completion rate) significantly reduces but does not eliminate post-transplant TB risk 5.